NASDAQ:JNCE - Jounce Therapeutics Stock Price, Price Target & More

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics (NASDAQ:JNCE) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.09. The company earned $11.20 million during the quarter, compared to analysts' expectations of $13.33 million. Jounce Therapeutics had a negative net margin of 47.73% and a negative return on equity of 19.90%. View Jounce Therapeutics' Earnings History.

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Jounce Therapeutics.

5 brokerages have issued 12-month price targets for Jounce Therapeutics' stock. Their forecasts range from $13.00 to $35.00. On average, they expect Jounce Therapeutics' share price to reach $23.75 in the next twelve months. View Analyst Ratings for Jounce Therapeutics.

Some companies that are related to Jounce Therapeutics include REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Solid Biosciences (SLDB), Novavax (NVAX), Voyager Therapeutics (VYGR) and Fate Therapeutics (FATE).

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

News stories about JNCE stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jounce Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Jounce Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Redmile Group LLC (3.64%), BlackRock Inc. (3.52%), Omega Fund Management LLC (1.63%), venBio Select Advisor LLC (1.61%), Citadel Advisors LLC (0.90%) and Fosun International Ltd (0.49%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Spark Investment Management LLC, Omega Fund Management LLC, Parsons Capital Management Inc. RI, Parsons Capital Management Inc. RI, BlackRock Inc., Russell Investments Group Ltd. and Northern Trust Corp. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

JNCE stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Citadel Advisors LLC, Redmile Group LLC, Elephas Investment Management Ltd, Dimensional Fund Advisors LP, A.R.T. Advisors LLC, JBF Capital Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $11.11.

Jounce Therapeutics has a market capitalization of $376.81 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.